Patent · US Active

Modified exendins and uses thereof

US8716221B2 · kind B2 · utility

17Cited by

4References

8Claims

0Family size

Assignee

Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. · CN

Inventors

Aifeng Lv · Lianyungang, CN
Changan Sun · Shanghai, CN
Yali Wang · Lianyungang, CN

Key dates

Filing date	Dec 22, 2011
Grant date	May 6, 2014
Priority date	—
Expiry date	Jan 15, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.